Monday Stock Trading Overview
Monday’s trading session has seen notable movements in stocks across the board, particularly involving mega-cap companies like Amazon and Netflix.
Mega-Cap Movers (Market Cap $200B+)
- Amazon Com Inc (AMZN): Wells Fargo downgrades to equal weight: -2.61%
- Netflix, Inc. (NFLX): Barclays downgrades to underweight: -1.81%
Large-Cap Stock Movers (Market Cap $10B-$200B)
- Air Prods & Chem (APD): Surges on activist Mantle Ridge stake, upgrades: +8.92%
- RenaissanceRe Holdings Ltd (RNR): -9.89%
- Everest Re Group Ltd (EG): -8.97%
- MicroStrategy Inc (MSTR): Gains on Bitcoin jump: +8.21%
- Coupang LLC (CPNG): Bernstein upgrades, sees volatility as entry point: +5.55%
- Ke Holdings Inc (BEKE): -7.75%
- Bilibili Inc (BILI): -6.2%
- Mobileye Global (MBLY): -4.29%
- Xpeng Inc (XPEV): +1.33%
- Pfizer (PFE): Activist Starboard Value Takes $1B Stake – WSJ: +3.8%
Mid-Cap Stock Movers (Market Cap $2B-$10B)
- Arcadium Lithium (ALTM): Confirms approach by Rio Tinto (RIO): +35.88%
- Zeekr Intelligent Technology ADR (ZK): +16.06%
- Hims & Hers (HIMS): To join S&P SmallCap 600: +12.74%
- Vista Outdoor Inc (VSTO): To sell Revelyst to SVP: +9.83%
- Generac Holdings (GNRC): Upgraded at OTR Global: +7.75%
- RLX Technology DRC (RLX): +5.69%
- Oscar Health (OSCR): -6.26%
- Palomar Holdings Inc (PLMR): -6.2%
- Compass (COMP): -5.68%
Small-Cap Stock Movers (Market Cap $300M-$2B)
- Scholar Rock Holding Corp (SRRK): Apitegromab shows promise in SMA motor function trial: +315.16%
- Duckhorn Portfolio (NAPA): To be acquired by Butterfly Equity for $1.95 billion: +102.13%
- Nexters (GDEV): +11.75%
- MYT Netherlands Parent (MYTE): +14.04%
- Heritage Insurance Holdings (HRTG): -23.71%
- Canadian Solar (CSIQ): +17.49%
- JinkoSolar Holding Comp Ltd (JKS): +17.45%
- ACM Research Inc (ACMR): +13.7%
- Serve Robotics (SERV): +19.84%
- Atlas Crest Investment (ACIC): -15.54%
For real-time, market-moving news, join Investing Pro.
This article was generated with the support of AI and reviewed by an editor. For more information, see our T&C.
Comments (0)